Compounds > atorvastatin
Page last updated: 2024-08-24

atorvastatin and Cancer of Prostate

atorvastatin has been researched along with Cancer of Prostate in 39 studies

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (17.95)29.6817
2010's22 (56.41)24.3611
2020's10 (25.64)2.80

Authors

AuthorsStudies
Borre, M; Boström, P; Ettala, O; Fode, M; Helminen, M; Koskimäki, J; Kotsar, A; Lehtimäki, T; Löffeler, S; Marttila, T; Murtola, TJ; Pakarainen, T; Raittinen, PV; Rannikko, A; Riikonen, J; Ronkainen, H; Salonen, A; Seikkula, H; Siltari, A; Tammela, T; Østergren, P1
Cao, Y; Liu, L; Wang, H; Yin, H; Zhao, Z; Zhu, Z1
Alves, VS; Cardoso, TC; Monteiro, MMLV; Rocha, MA; Savio, LEB; Silva, CLM1
Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X1
Fode, M; Murtola, TJ; Riikonen, J; Siltari, A1
Auriola, S; Ilmonen, P; Lehtimäki, T; Murtola, T; Niemistö, K; Pennanen, E; Raittinen, P; Riikonen, J; Syvälä, H1
He, Z; Qi, P; Shen, F; Wang, Z; Yuan, J; Zeng, F; Zhai, Z1
Hong, JH; Jeong, IG; Kim, CS; Lim, B; Lim, JH; Yun, SC1
He, Z; Qi, P; Shen, F; Wang, Z; Xu, D; Zeng, F; Zhai, Z1
Auriola, S; Häkkinen, MR; Ilmonen, P; Murtola, TJ; Raittinen, PVH; Syvälä, H; Tammela, TLJ1
Chen, B; Feng, Y; Xing, D; Zhang, M1
Du, ZY; Farischon, C; Goodin, S; He, Y; Huang, HR; Kim, S; Li, DL; Wang, ZS; Zhang, K; Zhang, LY; Zheng, X1
Du, Z; Goodin, S; He, Y; Huang, H; Liu, Y; Wan, Z; Wang, Z; Wu, X; Xiang, H; Zhang, K; Zhang, L; Zheng, X1
Helminen, M; Isotalo, T; Kaipia, A; Koskimäki, J; Kujala, P; Murtola, TJ; Pakarainen, T; Riikonen, J; Syvälä, H; Tammela, TLJ; Tolonen, T1
Allott, EH; Freedland, SJ; Freeman, MR1
Murtola, TJ; Riikonen, J; Syvälä, H1
Chung, BI; Kim, JH1
Auriola, S; Knuuttila, E; Murtola, TJ; Riikonen, J; Syvälä, H1
Kopelovich, L; Li, W; McCormick, DL; Mehta, RG; Peng, X; Yuan, L1
Chintala, M; Chintala, R; Guda, M; Komarraju, AL; Mangamoori, LN; Rentala, S1
Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X1
Ghalali, A; Högberg, J; Stenius, U; Wiklund, F; Zheng, H1
Chen, S; Conney, AH; Cui, XX; Dipaola, RS; Goodin, S; He, Y; Huang, H; Li, D; Liu, Y; Van Doren, J; Wang, H; Zheng, X1
He, Z; Qi, P; Wang, Z; Yuan, J; Zhang, L1
Brereton, I; Chambers, SK; Chow, CW; Coughlin, GD; Doi, SA; Dunglison, NT; Esler, RC; Gardiner, RA; Gianduzzo, TR; Kienzle, N; Lavin, MF; Lu, M; Medcraft, RJ; Oyama, C; Payton, D; Perry-Keene, J; Richards, RS; Roberts, MJ; Samaratunga, H; Schirra, HJ; Yaxley, JW1
Du, Z; Farischon, C; Goodin, S; He, Y; Huang, H; Li, D; Zhang, K; Zheng, X1
Gao, XS; Gu, XB; Sun, SQ; Wang, W; Yu, H1
Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA1
Jeon, TI; Osborne, TF; Seo, YK; Zhu, B1
Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X1
Handal, J; Kwok, SC; Samuel, SP1
D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE1
Childress, C; Parikh, A; Rukstalis, D; Toepfer, N; Yang, W1
He, Z; Mangala, LS; Rohde, LH; Theriot, CA; Wu, H; Zhang, Y1
Adamovich, E; Butler, WM; Galbreath, RW; Kurko, B; Merrick, GS; Moyad, MA; Wallner, KE1
Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE1
Byun, SS; Han, BK; Hong, SK; Jeong, SJ; Lee, SE1
Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X1
Chen, MH; D'Amico, AV; Kantoff, PW1

Trials

9 trial(s) available for atorvastatin and Cancer of Prostate

ArticleYear
Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.
    BMJ open, 2022, 04-29, Volume: 12, Issue:4

    Topics: Androgen Antagonists; Androgens; Atorvastatin; Cholesterol; Clinical Trials, Phase III as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic

2022
Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.
    The journal of sexual medicine, 2019, Volume: 16, Issue:10

    Topics: Aged; Atorvastatin; Biomarkers, Tumor; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Organ Sparing Treatments; Penile Erection; Postoperative Complications; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Recovery of Function

2019
Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.
    Scientific reports, 2020, 07-21, Volume: 10, Issue:1

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Double-Blind Method; Fatty Acids; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipidomics; Lipoproteins; Male; Metabolome; Middle Aged; Neoplasm Grading; Prostate; Prostatic Neoplasms; Treatment Outcome

2020
Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-15, Volume: 27, Issue:18

    Topics: Aged; Atorvastatin; Chemotherapy, Adjuvant; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Prostatectomy; Prostatic Neoplasms

2021
Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.
    EBioMedicine, 2021, Volume: 68

    Topics: Aged; Atorvastatin; Chromatography, Liquid; Double-Blind Method; Finland; Humans; Male; Mass Spectrometry; Middle Aged; Pilot Projects; Prospective Studies; Prostatic Neoplasms; Testosterone; Treatment Outcome

2021
Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
    European urology, 2018, Volume: 74, Issue:6

    Topics: Aged; Antineoplastic Agents; Atorvastatin; Cell Proliferation; Chemotherapy, Adjuvant; Double-Blind Method; Finland; Humans; Kallikreins; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome

2018
Access and concentrations of atorvastatin in the prostate in men with prostate cancer.
    The Prostate, 2019, Volume: 79, Issue:12

    Topics: Administration, Oral; Aged; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Humans; Lactones; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Neoplasms

2019
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
    Contemporary clinical trials, 2016, Volume: 50

    Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Metformin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design

2016
Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
    The Journal of urology, 2007, Volume: 178, Issue:2

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aged; Atorvastatin; Cyclic Nucleotide Phosphodiesterases, Type 5; Denervation; Drug Therapy, Combination; Erectile Dysfunction; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microsurgery; Middle Aged; Penile Erection; Peripheral Nerves; Piperazines; Postoperative Complications; Prospective Studies; Prostate; Prostatectomy; Prostatic Neoplasms; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Vasodilator Agents

2007

Other Studies

30 other study(ies) available for atorvastatin and Cancer of Prostate

ArticleYear
Atorvastatin regulates the migration and invasion of prostate cancer through the epithelial-mesenchymal transformation and matrix metalloproteinase pathways.
    Investigative and clinical urology, 2022, Volume: 63, Issue:3

    Topics: Animals; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Male; Matrix Metalloproteinases; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms

2022
The blockage of downstream P2Y
    Life sciences, 2022, Oct-01, Volume: 306

    Topics: Adenosine Triphosphate; Atorvastatin; Cell Adhesion; Endothelial Cells; Humans; Male; Prostatic Neoplasms; Tumor Microenvironment; Uridine Triphosphate

2022
Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis.
    Toxicology and applied pharmacology, 2022, 10-01, Volume: 452

    Topics: Aspirin; Atorvastatin; Cell Cycle Proteins; Computational Biology; DNA Primase; Gene Expression Regulation, Neoplastic; Humans; Male; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Protein Serine-Threonine Kinases

2022
Atorvastatin Enhances Effects of Radiotherapy on Prostate Cancer Cells and Xenograft Tumor Mice Through Triggering Interaction Between Bcl-2 and MSH2.
    Medical science monitor : international medical journal of experimental and clinical research, 2020, Sep-01, Volume: 26

    Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Nude; MutS Homolog 2 Protein; Prostatic Neoplasms; Protein Interaction Maps; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays

2020
Atorvastatin Enhances Inhibitory Effects of Irradiation on Tumor Growth by Reducing MSH2 Expression Both in Prostate Cancer Cells and Xenograft Tumor Models.
    Anti-cancer agents in medicinal chemistry, 2022, Volume: 22, Issue:7

    Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Heterografts; Humans; Male; Mice; Mice, Nude; MutS Homolog 2 Protein; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays

2022
Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1α inhibition.
    Bioscience reports, 2017, Aug-31, Volume: 37, Issue:4

    Topics: Apoptosis; Atorvastatin; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Prostatic Neoplasms; Radiation Tolerance

2017
Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
    Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inhibitor of Apoptosis Proteins; Male; Metformin; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Survivin; Tumor Burden; Xenograft Model Antitumor Assays

2017
Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells.
    Pathology oncology research : POR, 2020, Volume: 26, Issue:1

    Topics: Apoptosis; Atorvastatin; Caffeine; Cell Movement; Cell Proliferation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PC-3 Cells; Phosphodiesterase Inhibitors; Prostatic Neoplasms

2020
Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?
    European urology, 2018, Volume: 74, Issue:6

    Topics: Atorvastatin; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prostatectomy; Prostatic Neoplasms

2018
Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinic
    European urology, 2019, Volume: 75, Issue:6

    Topics: Atorvastatin; Double-Blind Method; Humans; Male; Prostatectomy; Prostatic Neoplasms

2019
Re: Timu J. Murtola, Hemo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.
    European urology, 2019, Volume: 75, Issue:6

    Topics: Atorvastatin; Double-Blind Method; Humans; Male; Prostatectomy; Prostatic Neoplasms; Seminal Vesicles

2019
Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Atorvastatin; Autophagy; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Diterpenes; Down-Regulation; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Male; MicroRNAs; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Up-Regulation

2013
Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.
    Biochemical and biophysical research communications, 2013, Nov-22, Volume: 441, Issue:3

    Topics: AC133 Antigen; Aged; Antigens, CD; Antineoplastic Agents; Atorvastatin; Cell Adhesion; Cell Differentiation; Focal Adhesion Kinase 1; Glycoproteins; Heptanoic Acids; Humans; Hyaluronan Receptors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplastic Stem Cells; Peptides; Prostate; Prostatic Neoplasms; Pyrroles; rho-Associated Kinases; Tumor Cells, Cultured

2013
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
    Oncology reports, 2014, Volume: 31, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays

2014
Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells.
    Carcinogenesis, 2014, Volume: 35, Issue:7

    Topics: Adenosine Triphosphate; Atorvastatin; Blotting, Western; Carrier Proteins; Cell Movement; Cell Nucleus; Cell Proliferation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured

2014
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Heptanoic Acids; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays

2014
Atorvastatin induces autophagic cell death in prostate cancer cells in vitro.
    Molecular medicine reports, 2015, Volume: 11, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Autophagy; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microtubule-Associated Proteins; Prostatic Neoplasms

2015
Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells.
    Oncology reports, 2017, Volume: 37, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Apoptosis; Aspirin; Atorvastatin; Blotting, Western; Cell Proliferation; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoenzyme Techniques; Male; Mice; Mice, SCID; NF-kappa B; Phosphorylation; Prostatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Atorvastatin prolongs the lifespan of radiation‑induced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect.
    Oncology reports, 2017, Volume: 37, Issue:4

    Topics: Antioxidants; Apoptosis; Atorvastatin; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Prostatic Neoplasms; Radiation; Radiation Tolerance; Radiation-Protective Agents; Reactive Oxygen Species; Superoxide Dismutase; Transfection

2017
The influence of statin medications on prostate-specific antigen levels.
    Journal of the National Cancer Institute, 2008, Nov-05, Volume: 100, Issue:21

    Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans

2008
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
    Experimental cell research, 2009, Nov-01, Volume: 315, Issue:18

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection

2009
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
    Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:1

    Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays

2010
Atorvastatin activates heme oxygenase-1 at the stress response elements.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:2

    Topics: Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Female; Heme Oxygenase-1; Heptanoic Acids; Humans; Male; Oxidative Stress; Polyisoprenyl Phosphates; Promoter Regions, Genetic; Prostatic Neoplasms; Pyrroles; Signal Transduction; Transcriptional Activation; Up-Regulation

2012
Statins and prostate cancer diagnosis and grade in a veterans population.
    Journal of the National Cancer Institute, 2011, Jun-08, Volume: 103, Issue:11

    Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans

2011
Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription.
    Cancer biology & therapy, 2011, Oct-15, Volume: 12, Issue:8

    Topics: Atorvastatin; Autophagy; Cell Growth Processes; Diterpenes; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Pyrroles; TOR Serine-Threonine Kinases; Transcription, Genetic; Transcriptional Activation

2011
Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells.
    Journal of radiation research, 2012, Volume: 53, Issue:2

    Topics: Atorvastatin; Autophagy; Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Heptanoic Acids; Humans; Male; Prostatic Neoplasms; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents

2012
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Urology, 2005, Volume: 66, Issue:6

    Topics: Aged; Atorvastatin; Brachytherapy; Disease Progression; Disease-Free Survival; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prostatic Neoplasms; Pyrroles

2005
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
    Urologic nursing, 2006, Volume: 26, Issue:4

    Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis

2006
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 1

    Topics: Animals; Apoptosis; Atorvastatin; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays

2007
Aspirin and hormone therapy for prostate cancer.
    The New England journal of medicine, 2007, Dec-27, Volume: 357, Issue:26

    Topics: Androgen Antagonists; Aspirin; Atorvastatin; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Function Tests; Logistic Models; Male; Prostatic Neoplasms; Pyrroles

2007